Cargando…

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri(®)): a prospective, 6-months, open label, observational, non-interventional study

BACKGROUND: Epoprostenol AS (Veletri(®)), a thermostable epoprostenol formulation, provides better drug stability and improved clinical use compared to previous epoprostenol formulations. This study aims to expand clinical experience in the use of Veletri(®), especially regarding tolerability, safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Degering, Julia, Egenlauf, Benjamin, Harutyunova, Satenik, Benjamin, Nicola, Salkić, Amina, Xanthouli, Panagiota, Eichstaedt, Christina A., Seeger, Rebekka, Sitbon, Olivier, Grünig, Ekkehard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847036/ https://www.ncbi.nlm.nih.gov/pubmed/36653855 http://dx.doi.org/10.1186/s12931-022-02296-z

Ejemplares similares

Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis
por: Xanthouli, Panagiota, et al.
Publicado: (2022)

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
por: Xanthouli, Panagiota, et al.
Publicado: (2020)

Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension
por: Xanthouli, Panagiota, et al.
Publicado: (2023)

Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension
por: Xanthouli, Panagiota, et al.
Publicado: (2023)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
por: Eichstaedt, Christina A., et al.
Publicado: (2020)

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study
por: Fischer, Lukas, et al.
Publicado: (2018)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
por: Pan, Zixuan, et al.
Publicado: (2019)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2016)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis
por: Grünig, Ekkehard, et al.
Publicado: (2020)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
por: Xanthouli, Panagiota, et al.
Publicado: (2021)

The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review
por: Palevičiūtė, Eglė, et al.
Publicado: (2022)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2022)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients
por: Song, Jie, et al.
Publicado: (2020)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Identification of a New Intronic BMPR2-Mutation and Early Diagnosis of Heritable Pulmonary Arterial Hypertension in a Large Family with Mean Clinical Follow-Up of 12 Years
por: Hinderhofer, Katrin, et al.
Publicado: (2014)

Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease
por: Melzig, Claudius, et al.
Publicado: (2022)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study
por: Camara, Raquel Paulinetti, et al.
Publicado: (2023)

Epoprostenol/hydroxychloroquine/tocilizumab: Acute large bowel perforation, off-label use and lack of efficacy: case report
Publicado: (2020)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Improved Survival for Patients with Systemic Sclerosis–associated Pulmonary Arterial Hypertension: For Real?
por: Xanthouli, Panagiota
Publicado: (2022)

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)

Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial
por: Palevičiūtė, Eglė, et al.
Publicado: (2023)

Circulating MicroRNA Markers for Pulmonary Hypertension in Supervised Exercise Intervention and Nightly Oxygen Intervention
por: Grunig, Gabriele, et al.
Publicado: (2018)

Microbial challenge test of a novel epoprostenol sodium formulation
por: Bandilla, Dirk, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fe9ma830b819mdjvsh5tf0rhmk